What is NA Selank Amidate 30MG

NA Selank Amidate 30MG is a chemically modified version of the synthetic heptapeptide Selank, studied in research for its enhanced anxiolytic (anti-anxiety) and nootropic properties. It is intended exclusively for research use.

Regarding its chemical identity, NA has a molecular formula of C36H57N11O9 (Base Selank) and a molecular weight of 751.9 (Base Selank) g/mol. Its reported canonical sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro (N-Acetyl, C-Amidated). A confirmed CAS number is not available in open primary reference sources and is therefore omitted.

Its synonyms include NA.

Product for research use.

Mechanism of action of NA

NA Selank Amidate exerts its effects by modulating the expression of Interleukin-6 and altering the balance of serotonin, dopamine, and norepinephrine in the brain. It also regulates the enkephalin system, providing profound stress relief without the sedative effects of traditional anxiolytics.

Pharmacokinetics and pharmacodynamics of NA

The N-Acetyl and C-Amidated modifications protect the peptide from rapid enzymatic degradation by exopeptidases. This significantly increases its stability, allowing it to cross the blood-brain barrier more efficiently and prolonging its half-life and biological effect compared to base Selank.

Scientific evidence on NA

The available evidence on NA is preliminary and largely inconclusive, and should be interpreted with caution. The literature describes it as having been investigated for multiple indications in preclinical models.

While base Selank is an approved medication in Russia for generalized anxiety disorder, the NA-Amidate version is strictly a research chemical. Preclinical studies suggest it offers identical mechanisms of action but with far greater potency and duration in reducing behavioral stress markers.

NA applications in research

Ideal for (research context):
– In vitro and preclinical studies of its specific receptor pathways.
– Investigation of tissue repair, cell proliferation, and functional restoration in laboratory models.
– Comparative work with related peptides.

Not applicable for:
– clinical, diagnostic or therapeutic use.
– Any administration to humans or animals outside of an authorized research protocol.

Product for research use.

NA protocols in preclinical studies

The literature consulted does not include numerical doses from studies that can be cited for NA, so no trial schemes or quantities are specified.

The presentations of this product (30MG) refer only to the amount of lyophilized peptide per vial (or volume for liquids) and do not constitute a dosage recommendation. The design of any protocol, including concentrations and working volumes, is the responsibility of the researcher, based on their experimental objectives and the relevant primary literature.

Information provided exclusively for research purposes.

Reconstitution and manipulation of NA

As a general guideline for laboratory handling, lyophilized peptides such as NA are usually reconstituted with bacteriostatic water (sterile water with approximately 0.9% benzyl alcohol).

Add the solvent slowly down the side of the vial, letting it run over the lyophilized powder; avoid injecting the stream directly onto the powder.
Do not shake: gently rotate the vial until completely dissolved.
Adjust the solvent volume according to the desired working concentration, considering the 30MG contents of the vial.

These guidelines are for general technique and do not replace the internal procedures of each laboratory.

NA Stability and Storage

As a standard laboratory handling procedure for peptides:

Freeze-dried (unreconstituted): This is the most stable form. It is best preserved by freezing and protecting it from moisture and light for long-term storage.
Reconstituted: once in solution, the peptide is less stable and must be kept refrigerated, being used within a short period; for extended storage, freezing in aliquots is usually preferred.
Avoid repeated freeze-thaw cycles, as they can degrade the peptide.

Given that the molecule is characterized by rapid enzymatic degradation in biological media, careful cold chain management is especially relevant.

Documented NA security profile

The documented safety information in open sources for NA is limited and should be interpreted with caution, also considering that it is research material and not for clinical use.

Generally considered to have a favorable theoretical safety profile without the addiction, withdrawal, or motor-impairment risks associated with benzodiazepines. Unverified in clinical human trials.

Formal contraindications and adverse event rates are not available in the consulted literature, so no figures are reported.

NA in a comparative context

Compared to base Selank, NA Selank Amidate is vastly more stable and potent. Compared to Semax, Selank focuses primarily on reducing anxiety and stress-induced brain fog, whereas Semax is purely a cognitive stimulant.

History and development of NA

Developed by researchers looking to improve the bioavailability and half-life of Tuftsin analogues. The addition of the N-acetyl group and C-terminal amidation represents a standard biochemical upgrade applied to many fragile neuropeptides.